BioTools Innovator

BioTools InnovatorBioTools Innovator
BI

BioTools Innovator

An accelerator program for life science startups.

2023ActiveLos Angeles, USA

About

BioTools Innovator is an accelerator program focused on supporting life science startups. The program selects promising companies to provide them with resources and opportunities, including funding. The 2026 Accelerator cohort included 30 startups competing for $300K in funding.
Frequently asked

What does BioTools Innovator do?

BioTools Innovator is an accelerator program focused on supporting life science startups. The program selects promising companies to provide them with resources and opportunities, including funding. The 2026 Accelerator cohort included 30 startups competing for $300K in funding.

What is BioTools Innovator's revenue?

StartupHub estimates BioTools Innovator's annual revenue at $84K (range $20K to $127K, 27% confidence), based on comparable companies in the sector.

What is BioTools Innovator's valuation?

StartupHub estimates BioTools Innovator's effective valuation at $1.1M (range $750K to $1.8M, 12% confidence), based on comparable companies in the sector.

How much funding has BioTools Innovator raised?

BioTools Innovator has raised a total of $300K in funding. The most recent round on record is Funding Round.

Where is BioTools Innovator headquartered?

BioTools Innovator is headquartered in Los Angeles, California, USA.

When was BioTools Innovator founded?

BioTools Innovator was founded in 2023.

What industry does BioTools Innovator operate in?

BioTools Innovator operates in Life Sciences, Biotechnology, Healthcare, Biotech, MedTech, HealthTech.

Scores
Measured, not editorial
Agent Readiness
21/100

How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.

Star ratings come from visitors, one per person per profile, and are shown exactly as given: we do not weight, curate or filter them. Reviews are published in full alongside the rating that accompanied them.

Comments

No comments yet. Be the first to share your take.